Insufficient scRNA-seq data for expression of CYP26C1 at single-cell level.
Insufficient scRNA-seq data for expression of CYP26C1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
spleen | 99% | 32.70 | 239 / 241 | 0% | 0 | 0 / 0 |
uterus | 85% | 13.29 | 145 / 170 | 3% | 0.06 | 15 / 459 |
adipose | 83% | 11.25 | 1005 / 1204 | 0% | 0 | 0 / 0 |
kidney | 80% | 9.96 | 71 / 89 | 3% | 0.09 | 28 / 901 |
ovary | 66% | 6.52 | 119 / 180 | 13% | 0.24 | 57 / 430 |
breast | 79% | 10.02 | 364 / 459 | 0% | 0 | 0 / 1118 |
brain | 78% | 12.50 | 2051 / 2642 | 0% | 0 | 0 / 705 |
thymus | 77% | 6.97 | 501 / 653 | 1% | 0.02 | 5 / 605 |
bladder | 71% | 4.33 | 15 / 21 | 0% | 0.01 | 2 / 504 |
lung | 64% | 5.28 | 372 / 578 | 1% | 0.01 | 7 / 1155 |
prostate | 65% | 7.19 | 159 / 245 | 0% | 0 | 0 / 502 |
adrenal gland | 45% | 10.78 | 116 / 258 | 13% | 0.64 | 30 / 230 |
intestine | 54% | 4.74 | 517 / 966 | 0% | 0.00 | 1 / 527 |
liver | 50% | 3.16 | 112 / 226 | 0% | 0 | 0 / 406 |
esophagus | 45% | 2.82 | 652 / 1445 | 1% | 0.02 | 2 / 183 |
blood vessel | 46% | 3.24 | 612 / 1335 | 0% | 0 | 0 / 0 |
skin | 37% | 2.19 | 675 / 1809 | 2% | 0.05 | 10 / 472 |
pancreas | 36% | 2.05 | 119 / 328 | 0% | 0 | 0 / 178 |
stomach | 34% | 1.89 | 122 / 359 | 0% | 0 | 0 / 286 |
peripheral blood | 34% | 3.17 | 313 / 929 | 0% | 0 | 0 / 0 |
muscle | 22% | 1.07 | 173 / 803 | 0% | 0 | 0 / 0 |
heart | 20% | 0.97 | 169 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.06 | 2 / 80 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048284 | Biological process | organelle fusion |
GO_0034653 | Biological process | retinoic acid catabolic process |
GO_0006766 | Biological process | vitamin metabolic process |
GO_0048387 | Biological process | negative regulation of retinoic acid receptor signaling pathway |
GO_0016125 | Biological process | sterol metabolic process |
GO_0014032 | Biological process | neural crest cell development |
GO_0009952 | Biological process | anterior/posterior pattern specification |
GO_0007417 | Biological process | central nervous system development |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008401 | Molecular function | retinoic acid 4-hydroxylase activity |
GO_0020037 | Molecular function | heme binding |
GO_0070330 | Molecular function | aromatase activity |
GO_0001972 | Molecular function | retinoic acid binding |
Gene name | CYP26C1 |
Protein name | Cytochrome P450 26C1 (CYP26C1) (EC 1.14.14.1) Cytochrome P450 family 26 subfamily C member 1 (Cytochrome P450, family 26, subfamily C, polypeptide 1, isoform CRA_a) |
Synonyms | hCG_39535 |
Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals . RAs exist as at least four different isomers: all-trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the oxidation of atRA primarily at C-4 . Oxidation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination, thereby contributes to the regulation of atRA homeostasis and signaling (Probable). Able to metabolize other RAs such as 9-cis with high efficiency . Can oxidize all-trans-13,14-dihydroretinoate (DRA) to metabolites which could include all-trans-4-oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all-trans-18-hydroxy-DRA (By similarity). Shares sequence similarity with other CYP26 family members, but has higher affinity to 9-cis-RA and is much less sensitive to the inhibitory effects of ketoconazole . In cooperation with Cyp26a1, contributes to the CNS patterning and the development of regions of higher visual acuity (By similarity). . |
Accessions | A0A096LNL5 ENST00000651965.1 Q6V0L0 ENST00000624358.3 |